Track topics on Twitter Track topics that are important to you
Varicella Zoster Immune Globulin VARIZIG Administration Days After PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Varicella Zoster Immune Globulin VARIZIG Administration Days After articles that have been published worldwide.
We have published hundreds of Varicella Zoster Immune Globulin VARIZIG Administration Days After news stories on BioPortfolio along with dozens of Varicella Zoster Immune Globulin VARIZIG Administration Days After Clinical Trials and PubMed Articles about Varicella Zoster Immune Globulin VARIZIG Administration Days After for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Varicella Zoster Immune Globulin VARIZIG Administration Days After Companies in our database. You can also find out about relevant Varicella Zoster Immune Globulin VARIZIG Administration Days After Drugs and Medications on this site too.
Infants exposed to varicella zoster virus (VZV) in utero ≤5 days before or ≤48 hours after delivery and preterm infants are at high risk for varicella complications. An expanded-access program assessed varicella outcomes after administration of varicella zoster immune globulin (human) (VARIZIG) in a real-world setting.
Clinical observations from the international literature report that herpes zoster occurs after varicella vaccination in immunocompetent children. We present the case of a four-year-old immunocompetent girl who developed herpes zoster after she had received one dose of varicella-zoster virus live attenuated vaccine at the age of 15 months. Continued surveillance for herpes zoster among vaccinated persons is important to evaluate the varicella vaccination program and to detect any changes in the epidemiology ...
Infection with varicella zoster virus (VZV) in pregnancy may lead to serious outcomes both for the mother and the newborn. Targeted screening and vaccination of non-immune women during reproductive age could prevent varicella infection in pregnancy. Currently, no universal varicella screening of pregnant women is implemented in Norway, but serological testing in pregnancy is recommended in particular situations. We examined seroprevalence of VZV in a national pregnancy cohort in order to help assess a need ...
Herpes zoster is linked to amyloid-associated diseases, including dementia, macular degeneration, and diabetes mellitus, in epidemiological studies. Thus, we examined whether varicella zoster virus (VZV)-infected cells produce amyloid.
Stress-induced subclinical reactivation of varicella-zoster virus (VZV) has been studied previously. However, subclinical reactivation of VZV induced by the stress of pregnancy has not been investigated. The objective was to study varicella DNA and varicella antibody levels in mothers and their newborn babies. VZV immunoglobulin G (IgG) levels in 350 mother-newborn dyads were studied using indirect enzyme-linked immunosorbent assay testing. A subset of 73 dyads was selected, DNA was isolated from the serum ...
Transverse myelitis is a segmental, full-thickness inflammation of the spinal cord with various etiologies including varicella zoster virus infection. Symptoms can manifest as sensory deficits, severe lower back pain radiating down the legs, bowel/bladder incontinence, and extremity weakness. This case report is unique in that it highlights a patient who developed long-segment transverse myelitis after a varicella zoster virus infection which has not been previously reported in the literature.
Since patients with breakthrough varicella (BV) have mild symptoms, clinical diagnosis is difficult. In high vaccine coverage area, as BV occurs sporadically, point of care test is required for controlling varicella outbreak. In this study, the reliability of varicella zoster virus (VZV)-loop mediated isothermal amplification (LAMP) was evaluated for the rapid diagnosis of BV.
: Policy-makers in many countries have been wary of introducing varicella vaccination programs because of concerns that reduced exposures to varicella zoster virus could increase incidence herpes zoster (HZ) incidence. The U.S. introduced varicella vaccination in 1996 and has empiric evidence regarding this concern. : This comprehensive review provides background emphasizing the epidemiology of varicella and of HZ in the U.S. before and after introduction of their respective vaccines. The epidemiology is co...
Recent studies focusing on morbidity and mortality rates of immunocompromised children with Varicella Zoster virus (VZV) infections are scarce. We aimed to summarise our experience.
Introduction: Herpes zoster (HZ), or shingles, is localized disease characterized by unilateral radicular pain and a vesicular rash limited to the area of skin innervated by a single dorsal root or cranial sensory ganglion. Whereas varicella, or chickenpox, results from primary exogenous varicella-zoster virus (VZV) infection, HZ is caused by reactivation of endogenous VZV that has persisted in latent form within sensory ganglia following an earlier episode of chickenpox. The aim: To explore the clinical fe...
Herpes zoster (HZ) is caused by varicella-zoster virus ( VZV ) reactivation. In the United States, Zoster vaccine (ZOSTAVAX) is indicated for HZ prevention in patients ≥50 years.
Chickenpox is a highly contagious vaccine-preventable disease that can lead to severe complications, especially in immunocompromised patients. Varicella-zoster virus (VZV) vaccine appears to be safe and immunogenic in pediatric solid organ transplant recipients, but there are few data on the long-term vaccine-induced seroprotection.
Herpes zoster classically presents as a vesicular eruption along a single dermatome that correlates with the dorsal root ganglion in which varicella zoster virus (VZV) reactivates. Such cases most commonly involve a single thoracic dermatome, but other rare presentations of herpes zoster have been reported including multidermatomal herpes zoster. This letter reports a case of multidermatomal herpes zoster affecting cervical dermatomes C2-C5 and presents all previously published cases of multidermatomal herp...
Herpes zoster (HZ) is caused by reactivation of varicella zoster virus (VZV) that established latency in sensory and autonomic neurons during primary infection. In the Shingles Prevention Study (SPS), a large efficacy trial of live attenuated Oka/Merck zoster vaccine (ZVL), PCR-confirmed second episodes of HZ occurred in two of 660 placebo and one of 321 ZVL recipients with documented HZ during a mean follow-up of 3.13 years. An additional two ZVL recipients experienced a second episode of HZ in the Long-...
Although most complications of herpes zoster (HZ) are associated with the spread of varicella-zoster virus from the initially involved sensory ganglion, motor nerve impairment, such as limb weakness, is a rare but severe complication that is difficult to treat.
In South Korea, the population is rapidly aging and the prevalence of comorbidities has increased. We investigated longitudinal changes in the herpes zoster (HZ) considering demographic changes and comorbidities in the era of universal single-dose varicella vaccination.
Immunocompromised subjects are at increased risk for herpes zoster (HZ) and HZ-related complications, such as post herpetic neuralgia (PHN). We describe health utilities, health care resource utilization (HCRU), productivity loss and health care costs in recipients of autologous hematopoietic stem cell transplantation (Auto-HSCT) who developed confirmed HZ in the phase 3 clinical trial.
Although long-term antiviral prophylaxis is recommended to prevent varicella-zoster virus (VZV) infection in seropositive allogeneic and autologous hematopoietic cell transplantation (auto-HCT) patients, studies of VZV infections in pediatric auto-HCT patients are rare. This study aimed to investigate the incidence and characteristics of VZV infection in pediatric auto-HCT patients and explore the risk factors of VZV infection and its effect on survival outcome.
The recombinant adjuvanted zoster vaccine (RZV, trade name Shingrix) is preferentially recommended by the Advisory Committee on Immunization Practices to prevent herpes zoster and related complications in immunocompetent adults age 50 years and older. This article reviews efficacy and safety of the vaccine, its use in special populations, and how to prevent administration errors to answer the question "Which patients should receive the herpes zoster vaccine?"
Aim The aim of this study was to evaluate trends in admissions for patients with primary varicella infection in Irish hospitals. Methods The Hospital Inpatient Enquiry System was evaluated from Irish hospitals from 2005-2016 for patients with primary varicella infection. Results There were 2717 admissions with primary varicella infection. The average annual number of admissions was 226 for an incidence of 4.87/100,000. Average length of stay (ALOS) was 5-days. Sixty-two (2.5%) patients required intensive-ca...
Fingolimod (FTY) applied as treatment regimen of relapsing-remitting multiple sclerosis (RRMS) induces downregulation of sphingosine-1-phosphate receptors on the lymphocytes. As a result CC chemokine receptor type 7 (CCR7) expressing lymphocytes are retained within the peripheral lymph nodes thus suppressing their accumulation into the cerebrospinal fluid of multiple sclerosis (MS) patients and hampering disease progress. Unfortunately, MS patients treated with FTY suffer from an increased incidence of vari...